Christi Shaw, leader of Gilead’s cancer cell therapy unit, to depart

Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement.

Shaw, who took the Kite role in July 2019, had previously said that she was inspired to take the role in part by the experience of watching her sister fight cancer. Under her leadership, the once-embattled division, which makes personalized CAR-T treatments for blood cancers, has begun to be a significant contributor to Gilead’s overall business.

Shaw is leaving at the end of March. Gilead is conducting a search for her replacement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In